

DAFTAR PUSTAKA

1. WHO Classification of Tumours Editorial Board. Breast tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71:209–49.
3. Setyawan IB, Kurnia D, Setiaji K, Anwar SL, Purwanto DJ, Azhar Y, et al. Sociodemographic disparities associated with advanced stages and distant metastatic breast cancers at diagnosis in Indonesia: A cross-sectional study. *Ann Med Surg.* 2023;85:4211–7.
4. Anwar SL, Raharjo CA, Herviastuti R, Dwianingsih EK, Setyoheriyanto D, Avanti WS, et al. Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: A hospital-based study. *BMC Womens Health.* 2019;19.
5. Sinaga ES, Ahmad RA, Shivalli S, Hutajulu SH. Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. *Pan Afr Med J.* 2018;31.
6. Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Laporan nasional riset kesehatan dasar 2018. Jakarta: Kementerian Kesehatan RI; 2019.
7. Susanti M, Yustiana, Salmi. Profil kanker payudara di RSUP Dr M Djamil Padang pada tahun 2019. *Nusantara Hasana J.* 2022;2:101–8.
8. Hanggara MA, Hanum FJ, Adrial. Profil pasien kanker yang menjalani radioterapi di Rumah Sakit Universitas Andalas Padang tahun 2019–2020. *J Sains Teknol Kesehat.* 2024;1:354–65.
9. Bertozzi S, Londero AP, Vendramelli G, Orsaria M, Mariuzzi L, Pegolo E, et al. Retrospective case-cohort study on risk factors for developing distant metastases in women with breast cancer. *Cancer Med.* 2025;14.
10. Rakha EA, Tse GM, Quinn CM. An update on the pathological classification of breast cancer. *Histopathology.* 2023;82:5–16.
11. Zhang Y, Wang H, Zhao H, He X, Wang Y, Wang H. Prognostic significance and value of further classification of lymphovascular invasion in invasive breast cancer: A retrospective observational study. *Breast Cancer Res Treat.* 2024;206:397–410.
12. Kuhn E, Gambini D, Despini L, Asnaghi D, Runza L, Ferrero S. Updates on lymphovascular invasion in breast cancer. *Biomedicines.* 2023;11:968.
13. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. *AJCC cancer staging manual.* 8th ed. New York: Springer; 2017.
14. Shaaban AM, Shaw EC. Bench to bedside: Research influencing clinical practice in breast cancer. *Diagn Histopathol.* 2022;28:473–9.

15. Buyuk B, Jin S, Ye K. Epithelial-to-mesenchymal transition signaling pathways responsible for breast cancer metastasis. *Cell Mol Bioeng.* 2022;15.
16. Cheung KJ, Ewald AJ. Illuminating breast cancer invasion: Diverse roles for cell-cell interactions. *Curr Opin Cell Biol.* 2014;30:99–111.
17. Pal M, Bhattacharya S, Kalyan G, Hazra S. *Cadherin* profiling for therapeutic interventions in epithelial mesenchymal transition and tumorigenesis. *Exp Cell Res.* 2018;368:137–46.
18. Cao ZQ, Wang Z, Leng P. Aberrant N-cadherin expression in cancer. *Biomed Pharmacother.* 2019;118:109320.
19. ElMoneim HMA, Zaghoul NM. Expression of E-cadherin, N-cadherin and snail and their correlation with clinicopathological variants: An immunohistochemical study of 132 invasive ductal breast carcinomas in Egypt. *Clinics.* 2011;66:1765–71.
20. Farrag M, Anter A, Farrag N, Ibrahiem A. Switch of E-cadherin to N-cadherin expression in different molecular subtypes of breast invasive duct carcinomas and its correlation with clinicopathological features. *Indian J Pathol Microbiol.* 2021;64:38–46.
21. Qian X, Anzovino A, Kim S, Suyama K, Yao J, Hulit J, et al. N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. *Oncogene.* 2014;33:3411–21.
22. KM, Blaschuk OW, Cheong CM, Zannettino ACW, Vandyke K. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. *BMC Cancer.* 2018;18.
23. Luo WR, Wu AB, Fang WY, Li SY, Yao KT. Nuclear expression of N-cadherin correlates with poor prognosis of nasopharyngeal carcinoma. *Histopathology.* 2012;61:237–46.
24. Bock C, Kuhn C, Ditsch N, Krebold R, Heublein S, Mayr D, et al. Strong correlation between N-cadherin and CD133 in breast cancer: Role of both markers in metastatic events. *J Cancer Res Clin Oncol.* 2014;140:1873–81.
25. Jørgensen CLT, Forsare C, Bendahl PO, Falck AK, Fernö M, Lövgren K, et al. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression. *Breast Cancer Res Treat.* 2020;181:369–81.
26. Kumar P, Vishwanath M, Selvaraj S. Tumour budding with epithelial mesenchymal transition markers: A novel prognostic tool for breast carcinoma. *J Midlife Health.* 2025;16:186–91.
27. Kumar V, Abbas AK, Aster JC. *Robbins basic pathology.* 11th ed. Philadelphia: Elsevier; 2022.
28. Rima S, Rosfita R, Daan K, Kurniati HP, Annisa W. Differences in stage and age breast cancer patients among urban and rural in West Sumatera, Indonesia. 2023.

29. Lima JF, Nofech-Mozes S, Bayani J, Bartlett JMS. EMT in breast carcinoma: A review. *J Clin Med*. 2016;5:65.
30. Rakha EA, El-Sayed ME, Lee AHS, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. *J Clin Oncol*. 2008;26:3153–8.
31. Ragage F, Debled M, MacGrogan G, Brouste V, Desrousseaux M, Soubeyran I, et al. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer? *Cancer*. 2010;116:3093–101.
32. Cho SY, Park SY, Bae YK, Kim JY, Kim EK, Kim WG, et al. Standardized pathology report for breast cancer. *J Pathol Transl Med*. 2021;55:1–15.
33. Dutta SW, Volaric A, Morgan JT, Chinn Z, Atkins KA, Janowski EM. Pathologic evaluation and prognostic implications of nodal micrometastases in breast cancer. *Semin Radiat Oncol*. 2019;29:102–10.
34. Cserni G, Maguire A, Bianchi S, Ryska A, Kovács A. Sentinel lymph node assessment in breast cancer: An update on current recommendations. *Virchows Arch*. 2022;480:95–107.
35. Ahmed SS, Thike AA, Iqbal J, Yong WS, Tan B, Madhukumar P, et al. Sentinel lymph nodes with isolated tumour cells and micrometastases in breast cancer: Clinical relevance and prognostic significance. *J Clin Pathol*. 2014;67:243–50.
36. Wais R, Ali H. Axillary lymph node involvement in primary invasive breast carcinoma in a center in Baghdad Province. *Med J Babylon*. 2021;18:322–6.
37. Deberti M, Goupille C, Arbion F, Vilde A, Body G, Ouldamer L. Prognostic value of axillary lymph node metastases in invasive lobular breast carcinoma. *J Gynecol Obstet Hum Reprod*. 2023;52.
38. Radice GL. N-cadherin-mediated adhesion and signaling from development to disease: Lessons from mice. *Prog Mol Biol Transl Sci*. 2013;116:263–89.
39. Derycke LDM, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. *Int J Dev Biol*. 2004;48:463–76.
40. Kaszak I, Witkowska-Piłaszewicz O, Niewiadomska Z, Dworecka-Kaszak B, Toka FN, Jurka P. Role of cadherins in cancer: A review. *Int J Mol Sci*. 2020;21:7624.
41. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. *J Cell Sci*. 2008;121:727–35.
42. Lugli A, Zlobec I, Berger MD, Kirsch R, Nagtegaal ID. Tumour budding in solid cancers. *Nat Rev Clin Oncol*. 2021;18:101–15.
43. Sethi S, Sarkar FH, Ahmed Q, Bandyopadhyay S, Nahleh ZA, Semaan A, et al. Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. *Transl Oncol*. 2011;4:222–6.
44. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. *Mol Cancer*. 2016;15.

45. Reid SE, Kay EJ, Neilson LJ, Henze A, Serneels J, McGhee EJ, et al. Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. *EMBO J*. 2017;36:2373–89.
46. Albrecht LV, Green KJ, Dubash AD. Cadherins in cancer. In: *The cadherin superfamily: Key regulators of animal development and physiology*. Tokyo: Springer; 2016. p. 363–97.
47. Cao YW, Wan GX, Sun JP, Cui XB, Hu JM, Liang WH, et al. Implications of the Notch1-Snail/Slug epithelial-to-mesenchymal transition axis for lymph node metastasis in infiltrating ductal carcinoma. *Kaohsiung J Med Sci*. 2015;31:70–6.
48. Saadatmand S, De Kruijf EM, Sajet A, Dekker-Ensink NG, Van Nes JGH, Putter H, et al. Expression of cell adhesion molecules and prognosis in breast cancer. *Br J Surg*. 2013;100:252–60.
49. King JA, Shevde LA, Ofori-Acquah S, Watkins G, Jiang WG. Is N-cadherin expression important in ductal carcinoma? *Cancer Genomics Proteomics*. 2008;5:241–9.
50. Dahlan MS. *Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan*. 3rd ed. Jakarta: Salemba Medika; 2013.
51. Hardisman. *Tanya jawab metodologi penelitian kesehatan*. Yogyakarta: Gosyen Publishing; 2021.
52. Rasyd L, Agus S, Asri A. *Ekspresi p53 pada karsinoma payudara duktal invasif serta hubungannya dengan beberapa parameter patologik prognosis*. 2016.
53. Li CL, Wu CC, Kan JY, Chen FM, Hou MF, Chuang CH, et al. The impact of age group in breast cancer survival outcome according to neoadjuvant treatment response: A matched case-control study. *Kaohsiung J Med Sci*. 2022;38:277–82.
54. Aquino RGF, Pinheiro LGP, Ferreira MVP, Cavalcante DIM, Oliveira ALS, Gomes NN, et al. Ductal carcinoma of the breast: Morphological aspects according to the age. *J Bras Patol Med Lab*. 2015;51:252–7.
55. A'dilah Putri S, Asri A, Elliyanti A, Khambri D. Karakteristik klinikopatologi karsinoma payudara invasif di RSUP Dr. M. Djamil Padang periode 2018–2019. *J Ilmu Kesehat Indones*. 2022.
56. Ghiasvand R, Adami HO, Harirchi I, Akrami R, Zendejdel K. Higher incidence of premenopausal breast cancer in less developed countries; myth or truth? *BMC Cancer*. 2014;14.
57. Rivera-Franco MM, Leon-Rodriguez E. Delays in breast cancer detection and treatment in developing countries. *Breast Cancer (Auckl)*. 2018;12.
58. Zheng K, Tan JX, Li F, Li HY, Zeng XH, Ma BL, et al. Clinicopathologic factors related to the histological tumor grade of breast cancer in Western China. *Transl Oncol*. 2018;11:1023–33.
59. Omar A, Shebl O, Belal A, Darwish A. The incidence, clinicopathological characteristics and survival outcomes among young breast cancer patients in Alexandria, Egypt. *Ecancermedalscience*. 2026;20.

60. Nimbalkar VP, Rajarajan S, V PS, Alexander A, Kaluve R, Selvam S, et al. A comparative analysis of clinicopathological features and survival between pre and postmenopausal breast cancer from an Indian cohort. *Sci Rep.* 2023;13.
61. Akrami M, Meshksar A, Ghodduji JM, Safarpour MM, Tahmasebi S, Zangouri V, et al. Prognostic role of lymphovascular invasion in patients with early breast cancer. *Indian J Surg Oncol.* 2021;12:671–7.
62. Fidalgo F, Rodrigues TC, Pinilla M, Silva AG, Maciel MS, Rosenberg C, et al. Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. *Tumour Biol.* 2015;36:1835–48.
63. Novrial D, Nawangtantrini G, Sulistyo H, Sari HD, Djatmiko W. Association between axillary lymph node involvement and clinicopathological features of breast cancer among Indonesian women. *Med J Indones.* 2020;29:32–7.
64. Hutajulu SH, Prabandari YS, Bintoro BS, Wiranata JA, Widiastuti M, Suryani ND, et al. Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia. *PLoS One.* 2022;17.
65. Nindrea RD, Novera M, Syahrial S, Avilla NA, Putri FAR. Scoring system for predicting breast cancer risk among women in regions with limited healthcare infrastructure in Indonesia. *Asian Pac J Cancer Prev.* 2026;27:1459–67.
66. Li Z, Zheng W, Wang H, Cheng Y, Fang Y, Wu F, et al. Application of animal models in cancer research: recent progress and future prospects. *Cancer Manag Res.* 2021;2455–75.
67. Freitas AJA, Causin RL, Calfa S, Santana IVV, Balie M, Hirai W, et al. Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes. *Breast Cancer Res Treat.* 2025;212:237–50.
68. Fu L, Liu M, Yu X, Li X. Expressions of epithelial cell adhesion molecule, vimentin and N-cadherin in molecular subtypes of breast cancer and the correlation among them. *J Cent South Univ Med Sci.* 2016;41:1137–42.
69. Sigaeva A, Hutchings C, Cesnik A, Lilley KS, Lundberg E. Subcellular localization as a driver of protein function. *Nat Rev Mol Cell Biol.* 2026.
70. Libard S, Cerjan D, Alafuzoff I. Characteristics of the tissue section that influence the staining outcome in immunohistochemistry. *Histochem Cell Biol.* 2019;151:91–6.
71. Danbolt NC, Zhou Y, Furness DN, Holmseth S. Strategies for immunohistochemical protein localization using antibodies. *Glia.* 2016;2045–64.
72. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. *J Cell Sci.* 2005;118:873–87.
73. Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, et al. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. *Hum Pathol.* 2013;44:2581–9.
74. Guvakova MA, Prabakaran I, Wu Z, Hoffman DI, Huang Y, Tchou J, et al. CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ. *Breast Cancer Res Treat.* 2020;183:333–46.

75. Ovanez C. Sample size. In: Eltorai AEM, Liu T, Chand R, Kalva SP, editors. Translational interventional radiology. Amsterdam: Academic Press; 2023. p. 333–5. doi:10.1016/B978-0-12-823026-8.00010-9.
76. Mierzynska J, Piccinin C, Pe M, Martinelli F, Gotay C, Coens C, et al. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. *Lancet Oncol.* 2019;20:e685–98. doi:10.1016/S1470-2045(19)30656-4.
77. WHO Classification of Tumours Editorial Board. Head and neck tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2023.

